Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Graft-Versus-Host Disease (GVHD) Clinical Trials

A listing of Graft-Versus-Host Disease (GVHD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (39) clinical trials

People with acute Graft versus Host Disease (GVHD are asked to participate in a research study being conducted by Montefiore Medical Center

Phase N/A

This is an open-label, single-cohort, multicenter Phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory Grades II to IV acute GVHD.

Phase

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

Clinical Validation of Lophius Biosciences Kit T-Track CMV in Allo-HSCT Recipients

CMV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with significant morbidity and increased overall mortality. Patients are generally pre-emptively treated with antiviral medication after elevated levels of CMV copies in peripheral blood or plasma have been detected by quantitative PCR. However, these CMV reactivations are often subclinical ...

Phase N/A

Phase II Trial of Natalizumab (Tysabri ) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract

Natalizumab is a drug that was initially discovered as a treatment for autoimmune conditions. Natalizumab has been approved for use in patients with Multiple Sclerosis and Crohn's disease. In these diseases, the drug works to inhibit dysfunctional immune cells that are responsible for the symptoms seen in these diseases. Acute ...

Phase

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

This is a safety follow-up study through 180 days of remestemcel-L treatment in subjects who participated in MSB-GVHD001. This study will also explore duration of response over time. Subjects who participated in MSB-GVHD001 and received at least one dose of remestemcel-L as outlined in that protocol will be evaluated at ...

Phase

Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

The drug being tested in this study is called Vedolizumab. Vedolizumab (also called MLN0002) is approved for the treatment of adult participants with moderately to severely active UC and CD who achieved an inadequate response, had a loss of response, or were intolerant to conventional and/or biologic treatments. This study ...

Phase

Study of PRO 140 for Prophylaxis of Acute GVHD in Patients With AML or MDS Undergoing Allogeneic Stem-Cell Transplant.

In this study, 60 subjects will be randomized to receive either PRO 140 or placebo in a 1:1 ratio (i.e. 30 subjects per arm). PRO 140 or placebo will be administered as a 350 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the ...

Phase

A Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

A total of 48 subjects will be enrolled to receive orally administered KD025 200 mg QD (once daily), KD025 200 mg BID (twice daily), or KD025 400 mg QD. Study drug will be administered in 28-day cycles for 6 cycles (24 weeks). Subjects may receive study drug in the inpatient ...

Phase